Table 3.
Baseline demographics and tumor characteristics for patients with resected, pathologic stage III cutaneous melanoma receiving adjuvant immunotherapy (IO) stratified by time to adjuvant IO within the National Cancer Database (NCDB) cohort.
| Variable | Overall N=3712 |
Within 6 Weeks N=888 |
6–12 Weeks N=1666 |
Greater than 12 Weeks N=1158 |
p-value |
|---|---|---|---|---|---|
| Age (median [IQR]) | 59 [47, 68] | 61 [49, 70] | 58 [46, 68] | 57 [46, 67] | <0.001 |
| Sex (%) | 0.82 | ||||
| Male | 2273 (61.2) | 547 (61.6) | 1011 (60.7) | 715 (61.7) | |
| Female | 1439 (38.8) | 341 (38.4) | 655 (39.3) | 443 (38.3) | |
| Race (%) | 0.69 | ||||
| White | 3592 (96.8) | 858 (96.6) | 1619 (97.2) | 1115 (96.3) | |
| Black | 31 (0.8) | 9 (1.0) | 12 (0.7) | 10 (0.9) | |
| Other | 89 (2.4) | 21 (2.4) | 35 (2.1) | 33 (2.8) | |
| Year of Diagnosis (median [IQR]) | 2017 [2016, 2018] | 2018 [2017, 2018] | 2017 [2016, 2018] | 2016 [2016, 2017] | <0.001 |
| Breslow Depth (median [IQR]) | 3.2 [1.8, 5.5] | 3.2 [1.7, 5.5] | 3.2 [1.9, 5.6] | 3.1 [1.8, 5.2] | 0.38 |
| Ulceration (%) | 1895 (51.1) | 448 (50.5) | 835 (50.1) | 612 (52.8) | 0.33 |
| Histology (%) | 0.21 | ||||
| Superficial Spreading | 2315 (62.4) | 535 (60.2) | 1041 (62.5) | 739 (63.8) | |
| Nodular | 1078 (29.0) | 273 (30.7) | 488 (29.3) | 317 (27.4) | |
| Acral | 153 (4.1) | 31 (3.5) | 66 (4.0) | 56 (4.8) | |
| Other | 166 (4.5) | 49 (5.5) | 71 (4.3) | 46 (4.0) | |
| Site (%) | 0.002 | ||||
| Head/Neck | 624 (16.8) | 171 (19.3) | 263 (15.8) | 190 (16.4) | |
| Trunk | 1392 (37.5) | 314 (35.4) | 659 (39.6) | 419 (36.2) | |
| Upper Extremity | 718 (19.3) | 191 (21.5) | 319 (19.1) | 208 (18.0) | |
| Lower Extremity | 940 (25.3) | 208 (23.4) | 401 (24.1) | 331 (28.6) | |
| Other | 38 (1.0) | 4 (0.5) | 24 (1.4) | 10 (0.9) | |
| Charlson-Deyo Comorbidity Score (%) | 0.49 | ||||
| 0 | 3010 (81.1) | 711 (80.1) | 1350 (81.0) | 949 (82.0) | |
| 1 | 500 (13.5) | 132 (14.9) | 213 (12.8) | 155 (13.4) | |
| 2 | 111 (3.0) | 24 (2.7) | 56 (3.4) | 31 (2.7) | |
| 3+ | 91 (2.5) | 21 (2.4) | 47 (2.8) | 23 (2.0) | |
| Insurance Status (%) | 0.002 | ||||
| None | 102 (2.8) | 17 (1.9) | 48 (2.9) | 37 (3.2) | |
| Government | 1526 (41.6) | 408 (46.6) | 685 (41.6) | 433 (37.8) | |
| Private | 2037 (55.6) | 451 (51.5) | 912 (55.4) | 674 (58.9) | |
| Medicaid Expansion State (%) | 2001 (63.4) | 481 (62.3) | 920 (65.9) | 600 (60.9) | 0.04 |
| Patient Residence (%) | 0.33 | ||||
| Rural | 55 (1.5) | 8 (0.9) | 31 (1.9) | 16 (1.4) | |
| Urban | 610 (17.0) | 150 (17.4) | 281 (17.4) | 179 (16.1) | |
| Metropolitan | 2923 (81.5) | 702 (81.6) | 1306 (80.7) | 915 (82.4) | |
| Distance Traveled (median [IQR]) | 15.8 [7.3, 35.8] | 14.9 [7.3, 31.2] | 14.8 [6.7, 35.1] | 17.3 [8.0, 39.3] | 0.01 |
| Academic Center (%) | 1507 (40.6) | 339 (38.2) | 634 (38.1) | 534 (46.1) | <0.001 |
| Education Quartile (% not finishing high school) | 0.73 | ||||
| > 17.5% | 472 (15.1) | 110 (14.7) | 208 (15.0) | 154 (15.4) | |
| 10.9–17.5% | 806 (25.8) | 198 (26.5) | 355 (25.7) | 253 (25.4) | |
| 6.3–10.8% | 986 (31.5) | 218 (29.1) | 446 (32.2) | 322 (32.3) | |
| < 6.3% | 864 (27.6) | 222 (29.7) | 374 (27.0) | 268 (26.9) | |
| Income Quartile (%) | 0.90 | ||||
| < $40,227 | 412 (13.2) | 101 (13.5) | 176 (12.7) | 135 (13.5) | |
| $40,227 – $50,353 | 703 (22.5) | 162 (21.7) | 322 (23.3) | 219 (22.0) | |
| $50,354 – $63,332 | 821 (26.3) | 188 (25.2) | 370 (26.8) | 263 (26.4) | |
| > $63,332 | 1190 (38.1) | 295 (39.5) | 515 (37.2) | 380 (38.1) | |
| Clinical Stage (%) | 0.34 | ||||
| I | 545 (20.2) | 127 (19.7) | 248 (20.3) | 170 (20.5) | |
| II | 1339 (49.7) | 316 (49.1) | 629 (51.5) | 394 (47.5) | |
| III | 810 (30.1) | 201 (31.2) | 344 (28.2) | 265 (31.9) | |
| Path Sub-Stage (%) | <0.001 | ||||
| IIIA | 874 (23.9) | 203 (23.0) | 398 (24.2) | 273 (24.2) | |
| IIIB | 1216 (33.2) | 262 (29.7) | 539 (32.8) | 415 (36.7) | |
| IIIC | 1503 (41.1) | 395 (44.7) | 673 (40.9) | 435 (38.5) | |
| IIID | 65 (1.8) | 23 (2.6) | 35 (2.1) | 7 (0.6) | |
| Surgery (%) | 0.34 | ||||
| Wide Local Excision | 3592 (96.8) | 856 (96.4) | 1620 (97.2) | 1116 (96.4) | |
| Amputation | 120 (3.2) | 32 (3.6) | 46 (2.8) | 42 (3.6) | |
| Regional Nodal Surgery (%) | <0.001 | ||||
| SLNB alone | 1522 (42.2) | 520 (61.0) | 755 (46.5) | 247 (21.8) | |
| TLND, no SLNB | 1392 (38.6) | 231 (27.1) | 577 (35.6) | 584 (51.5) | |
| CLND after SLNB | 694 (19.2) | 102 (12.0) | 290 (17.9) | 302 (26.7) | |
| Nodes Examined (median [IQR]) | 5 [2, 17] | 3 [1, 8] | 4 [2, 15] | 12 [4, 22] | <0.001 |
| Nodes Positive (median [IQR]) | 1 [1, 2] | 1 [1, 2] | 1 [1, 2] | 1 [1, 2] | <0.001 |
| Adjuvant Radiation (%) | 235 (6.3) | 37 (4.2) | 84 (5.0) | 114 (9.8) | <0.001 |